VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 55,650 Shares of Arvinas, Inc. $ARVN

VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in shares of Arvinas, Inc. (NASDAQ:ARVN) by 371.0% in the 4th quarter, HoldingsChannel reports. The fund owned 70,650 shares of the company’s stock after buying an additional 55,650 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Arvinas were worth $838,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of ARVN. Nordea Investment Management AB grew its position in shares of Arvinas by 28.7% in the 3rd quarter. Nordea Investment Management AB now owns 557,742 shares of the company’s stock worth $4,730,000 after buying an additional 124,254 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new stake in shares of Arvinas in the 4th quarter worth approximately $1,245,000. JPMorgan Chase & Co. grew its position in shares of Arvinas by 475.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,779 shares of the company’s stock worth $1,830,000 after buying an additional 177,460 shares during the last quarter. BML Capital Management LLC bought a new stake in shares of Arvinas in the 3rd quarter worth approximately $426,000. Finally, Arbiter Partners Capital Management LLC bought a new stake in shares of Arvinas in the 3rd quarter worth approximately $3,858,000. Institutional investors own 95.19% of the company’s stock.

Key Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a Buy rating, signaling continued Wall Street confidence in upside potential. Arvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG Research
• Positive Sentiment: Arvinas and Pfizer’s breast cancer drug vepdegestrant was licensed to Rigel Pharmaceuticals in a deal that includes $85 million upfront and up to $320 million in milestones, which supports the value of Arvinas’ PROTAC platform and adds potential non-dilutive funding. Rigel strikes licensing deal for Pfizer and Arvinas’ breast cancer drug
• Neutral Sentiment: HC Wainwright modestly adjusted several earnings forecasts for Arvinas, including lower estimates for 2026-2029 and a small cut to FY2030 EPS, reflecting ongoing uncertainty around future profitability rather than a major new development.
• Neutral Sentiment: Arvinas recently beat Q1 EPS estimates, but revenue missed expectations and dropped sharply year over year, reinforcing that the company remains far from sustained profitability. Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Recent insider selling by the CEO, CFO, CAO, and another executive may be pressuring sentiment, even though the sales were disclosed as tax-withholding transactions tied to equity vesting. CEO insider filing

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ARVN shares. Zacks Research lowered shares of Arvinas from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 target price (up from $16.00) on shares of Arvinas in a research note on Wednesday, February 25th. Citigroup lifted their target price on shares of Arvinas from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Arvinas in a research report on Friday, April 10th. Finally, BTIG Research lifted their price target on Arvinas from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Arvinas has a consensus rating of “Hold” and an average target price of $14.69.

Insider Buying and Selling at Arvinas

In other news, Director John G. Houston sold 35,297 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $13.21, for a total value of $466,273.37. Following the sale, the director directly owned 1,122,183 shares of the company’s stock, valued at approximately $14,824,037.43. This represents a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Randy Teel sold 9,657 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $95,990.58. Following the completion of the sale, the chief executive officer directly owned 287,218 shares in the company, valued at approximately $2,854,946.92. This represents a 3.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 81,449 shares of company stock valued at $945,574 over the last three months. 7.30% of the stock is currently owned by corporate insiders.

Arvinas Price Performance

NASDAQ ARVN opened at $9.08 on Monday. Arvinas, Inc. has a twelve month low of $6.05 and a twelve month high of $14.51. The stock’s 50 day moving average is $10.97 and its 200 day moving average is $11.69. The firm has a market capitalization of $585.84 million, a PE ratio of -2.73 and a beta of 1.79.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.05. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The business had revenue of $15.60 million for the quarter, compared to analyst estimates of $16.61 million. During the same quarter in the previous year, the firm posted $1.14 earnings per share. Arvinas’s quarterly revenue was down 91.7% on a year-over-year basis. On average, research analysts anticipate that Arvinas, Inc. will post -2.85 earnings per share for the current year.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.